目的：分析玻璃体腔注射康柏西普联合视网膜激光光凝治疗糖尿病性黄斑水肿(diabetic macular edema，DME)的临床疗效。

方法：选取2015-06/2016-12我院确诊的DME患者73例80眼，根据治疗方式不同分为对照组和治疗组，对照组采用视网膜激光光凝治疗，治疗组采用玻璃体腔注射康柏西普联合激光光凝治疗。观察治疗前和治疗后3mo两组患者最佳矫正视力(BCVA)、视网膜厚度及并发症发生情况。

结果：治疗后3mo，两组患者BCVA均较治疗前显著改善，且治疗组患者BCVA显著优于对照组； 两组患者黄斑上方、下方、颞侧、鼻侧环状区的视网膜厚度和平均视网膜厚度均低于治疗前，且治疗组患者的平均视网膜厚度显著低于对照组，差异均有统计学意义(P<0.05)。随访期间，所有患者均未出现角膜水肿、前房炎性反应、视网膜出血、新生血管性青光眼、眼内炎等严重眼部并发症及全身不良反应。

结论：与单纯视网膜激光治疗相比，玻璃体腔注射康柏西普联合视网膜激光光凝治疗DME在改善视力、恢复视网膜功能方面效果更佳，且具有良好的安全性。

METHODS: Totally 73 patients(80 eyes)with type 2 diabetes and DME were enrolled in our hospital from June 2015 to December 2016, according to different treatment methods, and they were randomly divided into control group and treatment group. The control group were treated with retinal laser photocoagulation, and the treatment group were treated with intravitreal injection combined with laser photocoagulation. We observed the best corrected visual acuity(BCVA), retinal thickness and complications during the operation before treatment and 3mo after treatment.

RESULTS: At 3mo after treatment, the improvement of BCVA, the decreased value of average retinal thickness and retinal thickness at inferior, superior, temple and nasal in the treatment group were better than those in the control group and those after treatment was better than before(P<0.05). There was no statistically significant difference in the incidence of complications occurrence between the two groups(P>0.05). None of the patients had severe ocular complications such as corneal edema, anterior chamber inflammatory reaction, retinal hemorrhage, neonatal vascular glaucoma, endophthalmitis, etc. during follow up period.

CONCLUSION: Compared with applying laser photocoagulation alone, intravitreal injection of conbercept combined for DME is more effective with improved visual acuity, restored retinal function, and has good safety.